View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Dashboards
February 23, 2022

Artificial intelligence deals in the pharma sector decreased in H2 2021

During the second half of 2021, artificial intelligence deals accounted for 4.8% of all deals taking place in the sector.

By Data Journalism Team

In the second half of 2021 the number of artificial intelligence deals decreased by 2.9% from the same period in 2020.

This marks an acceleration in growth from the 27.9% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.

GlobalData’s deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During the second half of 2021, artificial intelligence deals accounted for 4.8% of all deals taking place in the sector. This represents an increase from the figure of 2.1% in second half of 2020.

GlobalData's thematic approach to sector activity seeks to group key company information on investments to see which industries are best placed to deal with any issues they may encounter.

These themes, of which artificial intelligence is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them, it becomes possible to ascertain which companies are leading the way on specific issues and which ones have some work to do.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU